carnitine has been researched along with Multiple Myeloma in 1 studies
Multiple Myeloma: A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lodi, A | 1 |
| Tiziani, S | 1 |
| Khanim, FL | 1 |
| Günther, UL | 1 |
| Viant, MR | 1 |
| Morgan, GJ | 1 |
| Bunce, CM | 1 |
| Drayson, MT | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Prospective Long-term Observational Study in Patients With Monoclonal Gammopathy of Undetermined Significance[NCT05539079] | 2,000 participants (Anticipated) | Observational | 2023-09-06 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 other study available for carnitine and Multiple Myeloma
| Article | Year |
|---|---|
Proton NMR-based metabolite analyses of archived serial paired serum and urine samples from myeloma patients at different stages of disease activity identifies acetylcarnitine as a novel marker of active disease.
Topics: Acetylcarnitine; Aged; Aged, 80 and over; Biomarkers, Tumor; Carnitine; Clinical Trials, Phase III a | 2013 |